Immunogenicity and safety of a novel monovalent high-dose inactivated poliovirus type 2 vaccine in infants: a comparative, observer-blind, randomised, controlled trial.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Following the proposed worldwide switch from trivalent oral poliovirus vaccine (tOPV) to bivalent types 1 and 3 OPV (bOPV) in 2016, inactivated poliovirus vaccine (IPV) will be the only source of protection against poliovirus type 2. With most countries opting for one dose of IPV in routine immunisation schedules during this transition because of cost and manufacturing constraints, optimisation of protection against all poliovirus types will be a priority of the global eradication programme. We assessed the immunogenicity and safety of a novel monovalent high-dose inactivated poliovirus type 2 vaccine (mIPV2HD) in infants.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Lancet Infect Dis

Title: The Lancet. Infectious diseases

Publisher: Elsevier BV

ISSN (Electronic): 1474-4457

ISSN (Print): 1473-3099

Publication date (Electronic): Mar 2016

Volume: 16

Issue: 3

Affiliations

[1 ] Hospital del Niño, Ciudad de Panama, Panama.

[2 ] Global Research in Infectious Diseases, Rio de Janeiro, Brazil.

[3 ] Center for Vaccinology (CEVAC), Ghent, Belgium.

[4 ] VaxTrials, Ciudad de Panama, Panama.

[5 ] Instituto de Pós Graduação Carlos Chagas, Rio de Janeiro, Brazil.

[6 ] Centers for Disease Control and Prevention, Atlanta, GA, USA.

[7 ] Bill & Melinda Gates Foundation, Seattle, WA, USA. Electronic address: Ananda.Bandyopadhyay@gatesfoundation.org.

Article

Publisher Item ID: S1473-3099(15)00488-0

DOI: 10.1016/S1473-3099(15)00488-0

PubMed ID: 26719058

SO-VID: 914d9c1d-240c-416b-abc8-c837065dc428

History

Data availability:

Comments

Comment on this article

scite_

Cited by 24

See all cited by

- Version 1